Dr. Jun Lu, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 365
Licensed in Connecticut since 2010, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
CT license 048382 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hartford Hospital Hartford, CT
- The Hospital of Central Connecticut New Britain, CT
- John Dempsey Hospital of the University of Connect Farmington, CT
Medical groups
- University of Connecticut Health Center (639 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 365
- Services billed
- 1,331
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 409 | 109 |
| Established patient office or other outpatient visit, 20-29 minutes | 293 | 268 |
| Destruction of precancer skin growth, 1 growth | 153 | 138 |
| Established patient office or other outpatient visit, 30-39 minutes | 136 | 112 |
| Destruction of skin growth, 1-14 growths | 52 | 49 |
| Biopsy of related skin growth, first growth | 45 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Farmington, CT | 151 |
| Triamcinolone Acetonide Other prescribers in Farmington, CT | 100 |
| Clobetasol Propionate Other prescribers in Farmington, CT | 90 |
| Hydrocortisone Other prescribers in Farmington, CT | 69 |
| Dupixent Syringe (dupilumab) Other prescribers in Farmington, CT | 62 |
| Metronidazole Other prescribers in Farmington, CT | 60 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Farmington, CT | 59 |
| Clindamycin Phosphate Other prescribers in Farmington, CT | 55 |
| Betamethasone Dipropionate Other prescribers in Farmington, CT | 39 |
| Skyrizi (risankizumab-rzaa) | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 18 payments worth $18,949 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $14,770 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $3,990 |
| Leo Pharma Inc. | $127 |
| Galderma Laboratories, L.P. | $25.92 |
| Pfizer Inc. | $18.93 |
| Lilly USA, LLC | $17.35 |
| Consulting Fee | $16,883 |
|---|---|
| Travel and Lodging | $1,561 |
| Food and Beverage | $505 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $7,163 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 4, 2025 | Consulting Fee | $3,990 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,820 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,910 |
| Regeneron Pharmaceuticals, Inc. Oct 13, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $585 |
| Regeneron Pharmaceuticals, Inc. Sep 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $569 |
| Regeneron Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $186 |
| Regeneron Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $186 |
| Regeneron Pharmaceuticals, Inc. Sep 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $35.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 7 companies. The companies reported $428,663 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company · Enrolling by invitation · NCT05735483 - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
AbbVie Inc. - Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)
Janssen Research & Development, LLC - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)
AbbVie Inc. - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. · Completed · NCT04206553 - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.